Advancing a novel class of therapeutics to engage disease targets and pathways that are undruggable by existing technologies
ALRN-6924: Our lead clinical candidate designed to reactivate
wild-type p53, the body's first line of defense against cancer
Stapled Peptide therapeutics have the potential to become a major class of drugs for oncology and other diseases
New Website Coming!
Please check back soon to see the progress!
View Our Current Site